Aktis Oncology, Inc. (AKTS) — AI News Sentiment & Analysis

First-in-human clinical imaging and dosimetry data for AKY-2519 demonstrated robust tumor uptake and limited normal tissue exposure, to be presented at the 2026 ASCO Annual Meeting (May 29-June 2). Further Phase 1b trial initiations are planned for H2 2026 with preliminary data in 2027. (Timing: Near-term (ASCO presentation by early June 2026), with follow-on trials and data readouts extending into 2027.)

Key catalysts include ongoing clinical trial advancements, presentation of AKY-2519 data at the upcoming ASCO meeting, and preliminary data readouts for AKY-1189 and AKY-2519 clinical trials. (Timing: ASCO presentation (May 29 – June 2, 2026), initiation of AKY-2519 basket trial (second half of 2026), preliminary data for AKY-1189 and AKY-2519 (first quarter 2027 and 2027).)

U.S. FDA Fast Track designation for AKY-1189 for locally advanced or metastatic urothelial cancer. This status allows for more frequent FDA interactions and potentially rolling submission of the Biologics License Application. (Timing: The Fast Track status affects the ongoing Phase 1b trial, with preliminary results from Part 1 expected in Q1 2027. Further regulatory milestones would follow this data release.)